U.S. Ventricular Assist Devices Market Size, Trends, Growth, Opportunities | Abbott and ABIOMED

The U.S. ventricular assist devices market size was worth USD 625.4 million in 2023 and is projected to grow at a CAGR of 9.7% during the forecast period.

The U.S. Ventricular Assist Devices (VADs) Market is experiencing significant growth due to rising cardiovascular disease prevalence and advancements in cardiac care technology. VADs are critical in managing end-stage heart failure, offering life-saving support to patients awaiting transplants or as a long-term solution for cardiac insufficiency.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂'𝗿𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴: 𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗣𝗗𝗙) 𝗦𝗮𝗺𝗽𝗹𝗲: https://www.fortunebusinessinsights.com/enquiry/sample/u-s-ventricular-assist-devices-market-107850

𝗞𝗲𝘆 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁

In December 2022, Johnson & Johnson Services, Inc. acquired ABIOMED, a leading provider of ventricular assist devices. This strategic acquisition allows Johnson & Johnson to expand its cardiac care portfolio and strengthen its position in the U.S. VAD market. ABIOMED's innovative technologies, including its Impella series, will play a pivotal role in enhancing patient outcomes and driving market growth.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗩𝗲𝗻𝘁𝗿𝗶𝗰𝘂𝗹𝗮𝗿 𝗔𝘀𝘀𝗶𝘀𝘁 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁

• Berlin Heart (Germany)
• ABIOMED (Johnson & Johnson Services, Inc.) (U.S.)
• Abbott (U.S.)
• Jarvik Heart, Inc. (U.S.)

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀

𝗥𝗶𝘀𝗶𝗻𝗴 𝗣𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗛𝗲𝗮𝗿𝘁 𝗙𝗮𝗶𝗹𝘂𝗿𝗲

Heart failure affects millions in the U.S., with increasing numbers requiring advanced interventions like VADs. This growing patient population is a key driver for the market.

𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀

Innovations such as smaller, more efficient, and biocompatible VADs are transforming cardiac care, making treatments safer and more effective for patients.

𝗚𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲𝘀 𝗮𝗻𝗱 𝗙𝘂𝗻𝗱𝗶𝗻𝗴

Increased funding for cardiac research and healthcare infrastructure enhancements is encouraging the adoption of ventricular assist devices, further boosting market growth.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀

𝗛𝗶𝗴𝗵 𝗖𝗼𝘀𝘁 𝗼𝗳 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗮𝗻𝗱 𝗣𝗿𝗼𝗰𝗲𝗱𝘂𝗿𝗲𝘀

The high cost of VADs and related surgical procedures remains a significant barrier for many patients, limiting access to advanced cardiac care.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗖𝗼𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀

Despite technological improvements, complications such as infection, bleeding, and device malfunction pose challenges, impacting patient adoption rates.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲

The comprehensive market report on the U.S. Ventricular Assist Devices Market provides detailed insights into market dynamics, trends, competitive landscape, and key segments, empowering stakeholders to make informed decisions.

𝗙𝗼𝗿 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗩𝗶𝘀𝗶𝘁: https://www.fortunebusinessinsights.com/u-s-ventricular-assist-devices-market-107850

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

Key players like ABIOMED, Abbott, and Jarvik Heart are investing heavily in research and development to introduce next-generation VADs. Collaborations and acquisitions are shaping the competitive landscape, allowing companies to expand their reach and improve product offerings.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀

𝗗𝗼𝗺𝗶𝗻𝗮𝗻𝗰𝗲 𝗼𝗳 𝗟𝗲𝗳𝘁 𝗩𝗲𝗻𝘁𝗿𝗶𝗰𝘂𝗹𝗮𝗿 𝗔𝘀𝘀𝗶𝘀𝘁 𝗗𝗲𝘃𝗶𝗰𝗲𝘀

By product, the left ventricular assist device (LVAD) segment holds a significant share of the U.S. market. LVADs are widely used due to their proven efficacy in managing left-sided heart failure, which is the most common type of cardiac insufficiency.

𝗥𝗶𝘀𝗶𝗻𝗴 𝗔𝗱𝗼𝗽𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗼𝘁𝗮𝗹 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗛𝗲𝗮𝗿𝘁𝘀

The development of total artificial hearts and bi-ventricular assist devices is gaining traction, offering solutions for patients with complex cardiac conditions.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀

The U.S. dominates the global VAD market, driven by robust healthcare infrastructure, high awareness levels, and a strong presence of leading manufacturers. States like California, Texas, and Florida are major contributors due to their large patient populations and advanced medical facilities.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲

• Development of compact and fully implantable VAD systems.
• Expansion into underserved regions to improve access to advanced cardiac care.
• Integration of AI for real-time monitoring and personalized treatment.
• Collaborative initiatives to reduce the cost of devices and procedures.

𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻

The U.S. Ventricular Assist Devices Market is at the forefront of innovation, addressing critical needs in cardiac care. With rising heart failure cases and technological advancements, the market is poised for substantial growth. Companies like Johnson & Johnson and Abbott are leading the way, setting new standards in patient outcomes and healthcare delivery. The future of VADs lies in continued innovation, affordability, and improved accessibility.

For more comprehensive insights, explore the U.S. Ventricular Assist Devices Market Report.

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗖𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝗰𝗲: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/u-s-ventricular-assist-devices-market-107850

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.:+1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.